Profile
Charan Behl has been Head-Technical Affairs of Elite Pharmaceuticals, Inc. since February 2007 and served as Executive Vice President and Chief Scientific Officer from March 2006 to February 2007.
He served as Vice President-Research and Development of Nastech Pharmaceutical Corporation, Inc. from January 1995 to July 1998 and Executive Vice President-Research and Development from July 1988 to January 2001 and Research Leader of Hoffman La Roche from April 1981 to November 1994.
Dr. Behl served as Assistant Research Scientist at the University of Michigan from 1978 to 1981 and Chairman of Nasal Drug Delivery Focus Group, which was formed in 1995 from 1995 to 2001.
Dr. Behl received a BS in Pharmaceutical Sciences from BITS-Pilani, an MS in Pharmaceutics from Duquesne University and a PhD in Pharmaceutical Sciences from the University of Michigan.
Former positions of Charan Behl
| Companies | Position | End |
|---|---|---|
MDRNA, Inc.
 MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Chief Tech/Sci/R&D Officer | 2000-12-31 |
| University of Michigan | Corporate Officer/Principal | 1980-12-31 |
Training of Charan Behl
| Birla Institute of Technology & Science | Undergraduate Degree |
| Duquesne University of The Holy Spirit | Graduate Degree |
| University of Michigan | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Commercial Services |
- Stock Market
- Insiders
- Charan Behl